Systemic Sclerosis Clinical Trial
Official title:
Effects of Intensive Aerobic and Muscle Endurance Exercise in Patients With Systemic Sclerosis - a Pilot Study
The hypothesis is that intensive aerobic and endurance muscle training is safe and
beneficial in patients with systemic sclerosis and concurrent interstitial lung disease.
The purpose of the study is to examine the effect of an eight week intensive aerobic
exercise and muscle endurance training program for patients with systemic sclerosis and
50-100 % of forced vital capacity.
A single subject experimental design with repeated systematic measures during a six week
A-phase (baseline period) and an eight week B-phase (intervention period) was used. Physical
capacity (six minute walk test), aerobic capacity (submaximal treadmill test) and muscle
endurance in shoulder and hip flexion (Functional Index 2) are assessed every other week
throughout the 14 week study. Activity limitation (Health Assessment Questionnaire), quality
of life (Short Form 36), Raynaud, Fatigue and Global Health during the recent week (Visual
Analogue Scales) are assessed at weeks 0, 6, 14. The exercise program includes aerobic
exercise corresponding to 15 on the Borg RPE scale (strenuous) and muscular endurance
training three times/week.
The purpose of the study is to examine the effect of an eight week intensive aerobic
exercise and muscle endurance training program for patients with systemic sclerosis and
50-100 % of forced vital capacity.
As systemic sclerosis is a very rare condition a Single Subject Experimental Design (SSED)
was used including a 6-week non-interventional A-phase where patients are assessed
systematically followed by an 8-week interventional B-phase where patients exercise three
days a week with continued systematic assessments. According to the 2-standard deviation (2
SD) band analysis, statistical analysis were performed for each patient individually.
Accordingly, a statistically significant change was detected if two consecutive assessments
in the B-phase exceeded the 2 standard deviations (SD) of the mean of the A-phase.
Patients were recruited from an ongoing study at the Karolinska University Hospital with the
purpose to screen all patients with systemic sclerosis in Stockholm for cardiovascular
disease. All patients meeting the inclusion criteria were invited to participate in this
exercise study.
Assessments:
The six minute walking test was used to assess physical capacity. A submaximal treadmill
test was used to estimate oxygen uptake in ml/kg x min. Muscle endurance was assessed by the
Functional Index 2 registering the number of correct performed repetitions in 7 muscle
groups. Pain, Raynaud's Phenomenon, fatigue and global disease impact on general well-being
was assessed by the Visual Analogue scale (VAS), 0-100. Limitations in activities of daily
living were assessed using the Health Assessment Questionnaire and the SF-36 was included to
assess perceived health.
The Exercise program:
The program starts with a 10-minute warm-up session with biking at an intensity
corresponding to perceived light exertion (10 on the Borg RPE, 6-20 scale). Thereafter, the
load is increased to reach an intensity corresponding to perceived heavy exertion (15 on the
Borg RPE scale) for an additional 15 minutes. During the last five minutes of the biking
session, the loads are reduced to an intensity corresponding to light exertion. Heart rate
was is recorded with a pulse watch (RS100 Polar) and peripheral saturation recorded with a
heart rate oximeter (Wristox 3100 Nonin Medical). During the first weeks patients start on
lower leads and increasing to the goal intensity. After the biking exercises, the
participants perform repetitive dynamic muscle resistance training with the goal to achieve
as many repetitions as possible in shoulder flexion and in hip flexion.
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03274076 -
Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc)
|
Phase 1/Phase 2 | |
Completed |
NCT04300426 -
Safety and Efficacy of Anaerobic Cultivated Human Intestinal Microbiome Transplantation in Systemic Sclerosis (ReSScue)
|
Phase 2 | |
Recruiting |
NCT06058091 -
RY_SW01 Cell Injection Therapy in Systemic Sclerosis
|
Phase 1/Phase 2 | |
Recruiting |
NCT04356755 -
Subcutaneous Injections of ASC to Heal Digital Ulcers in Patients With Scleroderma.
|
Phase 2 | |
Suspended |
NCT06210945 -
Study to Evaluate the Safety, Tolerability, and Activity of CM-101 in Patients With Systemic Sclerosis
|
Phase 2 | |
Not yet recruiting |
NCT05947682 -
Manufacturing of Allogeneic Adipose Tissue-derived Mesenchymal Stromal Cells for Treatment of Severe Systemic Sclerosis
|
N/A | |
Not yet recruiting |
NCT04303208 -
Sirtuin 3 and Sirtuin 7 in Systemic Sclerosis
|
N/A | |
Not yet recruiting |
NCT05177380 -
Efficacy of a Personalized Rehabilitation Program of Facial Involvement in Systemic Sclerosis
|
N/A | |
Recruiting |
NCT02551042 -
CSL Behring Sclero XIII
|
Phase 2 | |
Terminated |
NCT02246348 -
Evaluating Lung Doppler Signals in Patients With Systemic Sclerosis (SSc)
|
N/A | |
Terminated |
NCT02243111 -
Detecting Pulmonary Arterial Hypertension (PAH) in Patients With Systemic Sclerosis (SSc) by Ultrasound
|
N/A | |
Completed |
NCT01933334 -
Safety and Tolerability of Pirfenidone in Patients With Systemic SclerosisâRelated Interstitial Lung Disease (SSc-ILD) (LOTUSS)
|
Phase 2 | |
Completed |
NCT01468792 -
Hemodynamic Changes in Connective Tissue Disease
|
N/A | |
Terminated |
NCT00848107 -
Open-Label Study of Oral Treprostinil in Digital Ulcers
|
Phase 2 | |
Completed |
NCT00984932 -
Effect of Rosuvastatin on Systemic Sclerosis-related Pulmonary Hypertension
|
Phase 3 | |
Completed |
NCT00074568 -
Scleroderma Registry
|
||
Not yet recruiting |
NCT06412614 -
Evaluation of Patients With Systemic Sclerosis Without Specific or Associated Autoantibodies
|
||
Terminated |
NCT00622687 -
Effect of Different Iloprost Doses on Symptoms in Systemic Sclerosis
|
Phase 2 | |
Recruiting |
NCT04464434 -
Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis
|
Phase 4 | |
Recruiting |
NCT04246528 -
SPIN Self-Management Feasibility Trial With Progression to Full-scale Trial (SPIN-SELF)
|
N/A |